New Therapy for TNBC MBC Patients!

[Bestbird]

Good news!

If your cancer is Triple Negative (TNBC) and you’ve already had two or more therapies for metastatic disease, then you’re eligible to receive the newly-approved drug Trodelvy (Sacituzumab Govitecan – formerly IMMU-132).

Trodelvy, which is administered intravenously, consists of the chemotherapy drug irinotecan linked with an antibody targeted against TROP-2, a cell-surface protein that is expressed in more than 90% of TNBC. FDA approval was based upon a Phase 1/2 trial of 108 TNBC MBC patients who had previously undergone a median of three prior lines of therapy (80% of whom had visceral metastases). The results of the study determined that the median Progression-Free Survival (PFS) was 5.5 months and the median Overall Survival (OS) was 13.0 months. From: oncnursingnews.com/web-excl...

The above and similar information about approved MBC treatments and cutting edge research is in my book, “The Insider’s Guide to Metastatic Breast Cancer” which is also available as a complimentary .pdf. For information, please visit insidersguidembc.com/about

[Hidden]

Hi Bestbird! Thanks for sharing...My sister has MTNBC, so I will share this info with her!

[MMMP]

I’m so excited!!! My oncologist is looking into this for me!! Hoping to start ASAP on compassionate care- just finished Abraxane and Doxil with no luck!!!

[Bestbird in reply to MMMP]

Hoping you'll do beautifully on your next treatment!